前列腺床挽救放疗加雄激素剥夺与盆腔淋巴结治疗的生活质量结果:NRG Oncology/RTOG 0534 SPPORT
该研究分析SPPORT试验中前列腺切除术后可检测PSA男性患者的生活质量(QOL)。主要分析已确立在挽救性前列腺床放疗(PBRT)基础上加盆腔淋巴结放疗(PLNRT)和短期雄激素剥夺治疗(STADT)对生化无进展生存的获益。QOL结果显示各臂在1年和5年时无临床显著差异,但无进展生存的质量调整生命年(QALYs)支持STADT+PLNRT+PBRT。
要点
- SPPORT试验QOL分析显示,各治疗臂在1年和5年时QOL无临床显著差异。
- 含STADT的方案在6周和1年时性和激素领域QOL较差,但5年时无差异。
- 无进展生存的QALYs均值Arm1为5.5年、Arm2为6.2年、Arm3为6.6年,Arm3和Arm2较Arm1有统计学显著改善。
核心结论
- 尽管所有臂在放疗开始后6周QOL下降最明显且5年时仍低于基线,但各臂在1年和5年时QOL无临床显著差异。
- 无进展生存的QALYs支持STADT+PLNRT+PBRT用于前列腺癌挽救治疗。
研究设计与样本
- SPPORT试验的QOL分析,受试者为前列腺切除术后可检测PSA的前列腺癌男性。
- 受试者随机分配至Arm1(PBRT)、Arm2(4-6个月STADT+PBRT)或Arm3(PLNRT+STADT+PBRT)。
- QOL评估时间点为基线、放疗开始后6周、放疗结束后1年和5年,包括EPIC、Hopkins症状清单、EuroQol和QALYs。
- 采用配对t检验、Fisher精确检验和混合效应回归模型评估组间差异,并控制多重性。
主要发现
- EPIC肠道和泌尿评分在6周时下降,至1年和5年时回升,但未恢复至基线。
- 性和激素领域在6周和1年时组间有统计学显著差异,STADT组QOL评分较差,但5年时无差异。
- Hopkins症状清单在6周时的统计学显著差异无临床意义。
- 总生存的QALYs比较无统计学显著性;无进展生存的QALYs均值Arm1为5.5年、Arm2为6.2年、Arm3为6.6年,Arm3和Arm2较Arm1有统计学显著改善。
关键数值与推荐
- QOL评估工具包括EPIC、Hopkins症状清单、EuroQol和QALYs。
- 无进展生存QALYs均值:Arm1 5.5年,Arm2 6.2年,Arm3 6.6年。
临床怎么用
- 对于前列腺切除术后可检测PSA的患者,在PBRT基础上加STADT和PLNRT虽在短期内可能降低性和激素领域QOL,但1年和5年时无临床显著差异。
- 无进展生存QALYs支持STADT+PLNRT+PBRT的挽救治疗方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This is the quality of life (QOL) analysis of the SPPORT trial of men with a detectable prostate specific antigen after prostatectomy for prostate cancer. Primary analysis established a benefit of adding pelvic lymph node radiation therapy (PLNRT) and short-term androgen deprivation therapy (STADT) to salvage prostate bed radiation therapy (PBRT) for biochemical progression-free survival. METHODS AND MATERIALS: Subjects were randomized to Arm 1, PBRT, Arm 2, 4-6 months of STADT + PBRT, or Arm 3, PLNRT + STADT + PBRT. QOL was assessed at baseline, 6 weeks after the start of radiation therapy (RT), 1 and 5 years after the end of RT, including Expanded Prostate Cancer Index Composite, Hopkins Symptom Checklist, EuroQol, and quality-adjusted life years (QALYs). Statistical and clinical significance were calculated. Differences among arms were assessed using pairwise t-tests, Fisher's exact test, and mixed effects regression modeling, controlling for multiplicity. RESULTS: Six hundred forty four patients consented to QOL; 81% white and 54% <65 years. Expanded Prostate Cancer Index Composite, bowel and urinary scores decreased at 6 weeks then increased by years 1 and 5, although not to baseline. For sexual and hormonal domains, there were statistically significant differences between arms at 6 weeks and 1 year with STADT exhibiting poorer QOL scores, but no difference at 5 years. For Hopkins Symptom Checklist, statistically significant differences at 6 weeks were not clinically significant. Comparisons of QALYs for overall survival showed no statistical significance. However, freedom from progression QALY means were 5.5, 6.2, and 6.6 years for Arms 1, 2, and 3, respectively, with Arms 3 and 2 indicating statistically significant improvement over Arm 1. CONCLUSIONS: Although QOL generally declined the most among all arms at 6 weeks post-RT initiation, and remained lower than baseline at 5 years, there were no clinically significant differences in QOL among arms at 1 and 5 years. QALYs for freedom from progression favored STADT + PLNRT + PBRT for salvage treatment of prostate cancer.
引用
- Bruner DW, Karrison TG, Pollack A, et al. Quality of Life Results of Addition of Androgen Deprivation Therapy and Pelvic Lymph Node Treatment to Prostate Bed Salvage Radiation Therapy: NRG Oncology/RTOG 0534 SPPORT. Int J Radiat Oncol Biol Phys. 2026. PMID: 42448001. doi:10.1016/j.ijrobp.2026.06.3085
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。